Developing an Oncology Portfolio of Anticancer Drugs: The Experience of one Pharmaceutical Company

Autor:	Blackledge Gr
Rok vydání:	2005
Předmět:	Hormone Replacement Therapy business.industry Obstetrics and Gynecology Cancer Angiogenesis Inhibitors Antineoplastic Agents Pharmacology Biological effect medicine.disease Risk analysis (engineering) Neoplasms Dictionaries Pharmaceutic as Topic Humans Portfolio Medicine business
Zdroj:	Zentralblatt für Gynäkologie. 127:385-388
ISSN:	1438-9762 0044-4197
Popis:	For a company or institute that wishes to develop new anti-cancer agents, it is necessary to establish a portfolio of agents to reduce the risk of failure. Success rates for developing new agents are low and therefore different biological effect areas should be explored to ensure that at least one agent targeting cancer or a specific histological sub-type of cancer is effectively developed. This paper describes how one pharmaceutical company has developed a range of different agents with the ultimate aim of developing as many of these as is technically feasible into useful new medicines for the treatment of cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f214c16448040ae095ef38caf2942a4 https://doi.org/10.1055/s-2005-836858 Zobrazit plný text záznamu